Every material Form 8-K Insulet filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Insulet's Compensation Committee approved an amended and restated Annual Incentive Plan on December 11, 2025, effective January 1, 2026. The changes expand eligibility for prorated payments after retirement and for certain terminations without Cause, and increase the maximum award for participants.
Committee approved the amended and restated Annual Incentive Plan on December 11, 2025, effective January 1, 2026.
Maximum award for participants was increased; the filing does not state the new amount.
Changes also clarify the definition of "for Cause" termination and strengthen compensation recoupment language.
Insulet reported third-quarter 2025 revenue of $706.3 million, up 29.9%, and net income of $87.6 million, or $1.24 per diluted share, compared with $1.08 a year earlier. The company raised its full-year 2025 total revenue growth guidance to 28% to 29% in constant currency, from 24% to 27%, which supports the strong quarter for shareholders, though adjusted EBITDA margin fell 50 basis points.
Q3 2025 revenue of $706.3 million rose 29.9%, or 28.2% in constant currency, above the high end of the 22% to 25% constant currency guidance range
Q3 net income of $87.6 million, or $1.24 per diluted share, versus $77.5 million, or $1.08 per diluted share, a year earlier
Full-year 2025 total revenue growth guidance raised to 28% to 29% in constant currency from 24% to 27%
Adjusted operating margin guidance for 2025 narrowed to 17.3% to 17.5% from 17.0% to 17.5%
Insulet Corporation's board appointed Robbie Huffines, a former JP Morgan Chase investment banking executive, as a Class II director effective October 31, 2025. He was also named to the board's Audit Committee and will stand for election at the 2027 annual meeting.
Appointed by the board on October 21, 2025; effective October 31, 2025
Named to the Audit Committee, effective October 31, 2025
Previously Global Chair of Investment Banking at JP Morgan Chase, retiring in 2024
Receives non-employee director cash and equity compensation under the company's program
Insulet said Flavia Pease, currently a director and former CFO of Charles River Laboratories, will succeed Ana Chadwick as Executive Vice President and Chief Financial Officer effective September 30, 2025, and Ms. Chadwick will stay on as a Senior Advisor. The company also said it expects to exceed its previously issued third quarter 2025 total revenue growth guidance, driven by strong new customer starts in the U.S. and international markets.
Flavia Pease becomes CFO effective September 30, 2025; she will resign from the Board on starting employment.
Ana Chadwick remains with the company as a Senior Advisor and is expected to receive severance and a one-time cash payment tied to equity vesting May 1, 2026.
Pease's offer includes a $1,325,000 cash sign-on award and a $3,000,000 target equity sign-on award, plus a $762,500 prorated annual equity award and a $715,000 base salary.
Insulet expects to exceed prior Q3 2025 total revenue growth guidance and will report full results and a full-year outlook update on November 6, 2025.
Insulet reported second-quarter 2025 revenue of $649.1 million, up 32.9% from a year earlier, and raised its full-year 2025 total revenue growth guidance to 24% to 27% in constant currency, from 19% to 22%. GAAP net income fell to $22.5 million, or $0.32 per diluted share, from $188.6 million, or $2.59, a year earlier; that prior-year figure included a tax benefit, and this year's quarter included an $84.4 million loss on extinguishment of debt. Shareholders face a mixed picture: sales and adjusted earnings rose, while GAAP profit declined sharply.
Total Omnipod revenue was $639.0 million, up 33.0%; U.S. Omnipod revenue was $453.2 million, up 28.7%, and International Omnipod revenue was $185.8 million, up 45.0%.
Full-year 2025 adjusted operating margin guidance was raised to 17.0% to 17.5% from about 16.5%.
Adjusted net income was $83.7 million, or $1.17 per diluted share, compared with $38.3 million, or $0.55, a year earlier.
The company initiated redemption of the remaining $380 million principal of its convertible notes and refinanced its Term Loan B.
Insulet entered an amendment on June 6, 2025 replacing $481.25 million of existing term loans with new term loans carrying a margin 0.50% lower, and reduced the revolving loan margin. The company also issued notice to redeem all of its 0.375% Convertible Senior Notes due 2026 on August 20, 2025, at 100% of principal plus accrued interest, and terminated related capped call transactions. The filing gives no earnings figures, so the effect on shareholders is mainly lower borrowing costs and possible stock trading activity from hedge unwinds.
June 6, 2025: Eighth Amendment to Credit Agreement replaces $481.25 million of term loans; new term SOFR margin is 2.00% with a 0.00% floor
Revolving loan margin range reduced from 2.00%-2.50% to 1.50%-2.00% for term SOFR loans
Redemption Date of August 20, 2025 for all 0.375% Convertible Senior Notes due 2026, at 100% of principal plus accrued interest
Capped call transactions terminated; counterparties may sell common stock in the open market as they unwind hedges
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Insulet filing is on SEC EDGAR ↗. 8-K briefs of other companies →